Literature DB >> 24523838

Future therapies: Early trials and basic science.

Karl-Erik Andersson1.   

Abstract

Pharmacotherapeutic options for overactive bladder (OAB) include antimuscarinics and the beta3-adrenoceptor agonist mirabegron. Research and development of novel therapeutic options for OAB continues to be an active field. This review summarizes recent research with the existing therapies as well as the most promising agents in development.

Entities:  

Year:  2013        PMID： 24523838      PMCID： PMC3919188          DOI： 10.5489/cuaj.1617

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  4 in total

Review 1.  NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.

Authors:  Neal Shore
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

2.  Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Authors:  Paul Abrams; Con Kelleher; David Staskin; Tomasz Rechberger; Richard Kay; Reynaldo Martina; Donald Newgreen; Asha Paireddy; Rob van Maanen; Arwin Ridder
Journal:  Eur Urol       Date:  2014-02-19       Impact factor: 20.096

3.  Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Authors:  Mostafa M Elhilali; Peter Pommerville; Richard C Yocum; Rosemina Merchant; Claus G Roehrborn; Samuel R Denmeade
Journal:  J Urol       Date:  2012-11-07       Impact factor: 7.450

Review 4.  Imidafenacin for the treatment of overactive bladder.

Authors:  Umberto Leone Roberti Maggiore; Carolina Scala; Pier Luigi Venturini; Simone Ferrero
Journal:  Expert Opin Pharmacother       Date:  2013-05-06       Impact factor: 3.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.